doi: 10.1111/j.1476-5381.1992.tb14201.x.
The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988
Affiliations
- PMID: 1350747
- PMCID: PMC1908629
- DOI: 10.1111/j.1476-5381.1992.tb14201.x
Item in Clipboard
The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988
Br J Pharmacol.
1992 Jan.
Abstract
The ability of a selective cholecystokininB (CCKB) receptor antagonist, CI-988, to block benzodiazepine withdrawal effects was examined in mice. The discontinuation of twice daily administration of diazepam (1 mg kg-1, i.p.) induced withdrawal anxiogenesis and a proconvulsant effect. In contrast, no such effects were seen following withdrawal from similar administration of CI-988. However, CI-988 dose-dependently (0.001-1.0 mg kg-1, s.c.) antagonized both the anxiogenesis and the proconvulsant effect following diazepam-withdrawal.
Similar articles
-
The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.Br J Pharmacol. 1991 Sep;104(1):239-45. doi: 10.1111/j.1476-5381.1991.tb12413.x. Br J Pharmacol. 1991. PMID: 1686205 Free PMC article.
-
Anxiolytic effects of CCK-B antagonists.Neuropeptides. 1991 Jul;19 Suppl:65-73. doi: 10.1016/0143-4179(91)90084-v. Neuropeptides. 1991. PMID: 1679211
-
Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.Psychopharmacology (Berl). 1993;112(4):452-4. doi: 10.1007/BF02244893. Psychopharmacology (Berl). 1993. PMID: 7871056
-
Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists.Neuropeptides. 1991 Jul;19 Suppl:85-9. doi: 10.1016/0143-4179(91)90087-y. Neuropeptides. 1991. PMID: 1679213 Review. No abstract available.
-
Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome.CNS Drug Rev. 2004 Fall;10(3):219-29. doi: 10.1111/j.1527-3458.2004.tb00023.x. CNS Drug Rev. 2004. PMID: 15492772 Free PMC article. Review.
Cited by
-
Targeted invalidation of CCK2 receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test.Psychopharmacology (Berl). 2005 Sep;181(2):347-57. doi: 10.1007/s00213-005-2255-x. Epub 2005 Oct 14. Psychopharmacology (Berl). 2005. PMID: 15830228
-
Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats.Psychopharmacology (Berl). 1995 Mar;118(1):57-64. doi: 10.1007/BF02245250. Psychopharmacology (Berl). 1995. PMID: 7597123
-
The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.Psychopharmacology (Berl). 1997 Feb;129(3):243-8. doi: 10.1007/s002130050186. Psychopharmacology (Berl). 1997. PMID: 9084062 Clinical Trial.
-
Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice.Psychopharmacology (Berl). 2003 Aug;168(4):417-25. doi: 10.1007/s00213-003-1453-7. Epub 2003 Apr 23. Psychopharmacology (Berl). 2003. PMID: 12709779
-
The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.Psychopharmacology (Berl). 1993;110(4):409-14. doi: 10.1007/BF02244646. Psychopharmacology (Berl). 1993. PMID: 7870910
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
